Top

Journal of Cancer Research and Clinical Oncology

Published in:

01-12-2012 | Original Paper

Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case–control study Epilymph

Authors: Nikolaus Becker, Paul Schnitzler, Paolo Boffetta, Paul Brennan, Lenka Foretova, Marc Maynadié, Alexandra Nieters, Anthony Staines, Yolanda Benavente, Pierluigi Cocco, Silvia de Sanjose

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2012

Abstract

Background

We have recently reported from Epilymph, a multicentre case–control study of lymphoma conducted in six European countries, a significant association between NHL and self-reported history of past or present HBV infection based on questionnaire data from face-to-face interviews.

Methods

To corroborate this observation, we used the data and blood specimen from Epilymph to investigate the associations between serological indicators of HBV infection with risk of Hodgkin lymphoma, non-Hodgkin lymphoma (NHL) and specific lymphoma entities. For 1,518 cases and 1,496 controls with sufficient amount of serum or plasma, we tested HBs-antigen, anti-HBc and anti-HBs to distinguish between current or past infection and immunity by vaccination. Statistical analysis was carried out with unconditional logistic regression.

Results

We found a positive association of a past HBV infection with multiple myeloma (MM, OR = 1.97, 95 % CL = 1.16–3.37). Non-significant associations were found between past HBV infection and B-cell chronic lymphocytic leukaemia (B-CLL, OR = 1.33, 95 % CL = 0.82–2.16) and T-cell NHL (OR = 1.59, 95 % CL = 0.65–3.90), as well as between current HBV infection and NHL (OR = 1.49, 95 % CL = 0.65–3.41), B-NHL (OR = 1.58, 95 % CL = 0.69–3.64) and diffuse large B-cell lymphoma (DLBCL, OR = 1.50, 95 % CL = 0.47–4.82). Subjects having self-reported HBV infection were serological positive in 75 % of cases and 80 % of controls. For vaccination, the corresponding figures were 49 and 54 %, respectively.

Conclusion

The present results support previous reports of an association between a history of HBV infection with an elevated lymphoma risk and add multiple myeloma to the list of potentially virus-associated lymphoma entities.

Alexander DD, Mink PJ, Adami H-O, Chang ET, Cole P, Mandel JS, Trichopoulos D (2007) The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer 120:1–39PubMedCrossRef

Becker N, Deeg E, Rüdiger T, Nieters A (2005) Medical history and risk for lymphoma: results of a population-based case-control study in Germany. Eur J Cancer 41:133–142PubMedCrossRef

Becker N, Fortuny J, Alvaro T, Nieters A, Maynadié M, Foretova L, Staines A, Brennan P, Boffetta P, Cocco P, de Sanjosé S (2009) Medical history and risk of lymphoma: results of a European case-control study (EPILYMPH). J Cancer Res Clin Oncol 135(8):1099–1107PubMedCrossRef

Besson H, Brennan P, Becker N, Nieters A, De Sanjosé S, Font R, Maynadie M, Foretova L, Cocco PL, Stains A, Vornanen M, Boffetta P (2006) Tobacco smoking, alcohol drinking and non-Hodgkin’s lymphoma: a European multicenter case-control study (Epilymph). Int J Cancer 119:901–908PubMedCrossRef

Caillard S, Agodoa LY, Bohen EM, Abbott KC (2006) Myeloma, Hodgkin disease, and lymphoid leukemia after renal transplantation: characteristics, risk factors and prognosis. Transplantation 81:888–895PubMedCrossRef

Caligaris-Cappio F, Ghia P (2008) Novel insights in chronic lymphocytic leukemia: are we getting closer to understanding the pathogenesis of the disease? J Clin Oncol 26:4497–4503PubMedCrossRef

Chang M-H (1998) Chronic Hepatitis virus infection in children. J Gastroenterol Hepatol 13:541–548PubMedCrossRef

Cocco P, Piras G, Monne M, Uras A, Gabbas A, Ennas MG, Palmas A, Murineddu M, Collu S, Melis M, Rais M, Todde P, Cabras MG, Angelucci E, Massarelli G, Nieters A (2008) Risk of malignant lymphoma following viral hepatitis infection. Int J Hematol 87:474–483PubMedCrossRef

de Sanjose S, Benavente Y, Vajdic CM, Engels EA, Morton LM, Bracci PM, Spinelli JJ, Zheng TZ, Zhang YW, Franceschi S, Talamini R, Holly EA, Grulich AE, Cerhan JR, Hartge P, Cozen W, Boffetta P, Brennan P, Maynadie M, Cocco P, Bosch R, Foretova L, Staines A, Becker N, Nieters A (2008) Hepatitis C and non-Hodgkin lymphoma among 4784 cases and 6269 controls from the international lymphoma epidemiology consortium. Clin Gastroenterol Hepatol 6(4):451–458PubMedCrossRef

Engels EA, Cho ER, Jee SH (2010) Hepatitis B virus infection and risk of non-Hodgkin lymphoma in South Korea: a cohort study. Lancet Oncol 11:827–834PubMedCrossRef

Fortuny J, de Sanjosé S, Becker N, Maynadié M, Cocco PL, Staines A, Foretovea L, Vornanen M, Brennan P, Nieters A, Alvaro T, Boffetta P (2006) Statin use and risk of lymphoid neoplasms: results from the European case-control study EPILYMPH. Cancer Epidemiol Biomarkers Prev 15(5):921–925PubMedCrossRef

Franceschi S, Lise M, Trépo C, Berthillon P, Chuang S-C, Nieters A, Travis RC, Vermeulen R, Overvad K, Tjønneland A, Olsen A, Bergmann MM, Boeing H, Kaaks R, Becker N, Trichopoulou A, Lagiou P, Bamia C, Palli D, Sieri S, Panico S, Tumno R, Sacerdote C, Bueno-de-Mesquita B, Peeters PHM, Rodriguez L, Barroso LL, Dorronsoro M, Sánchez M-J, Navarro C, Barricarte A, Regnér S, Borgquist S, Melin B, Hallmans G, Khaw K-T, Wareham N, Rinaldi S, Hainaut P, Riboli E, Vineis P (2010) Infection with Hepatitis B and C viruses and risk of lymphoid malignancies in the European prospective investigation into cancer and nutrition (EPIC). Cancer Epidemiol Biomarkers Prev 20(1):208–214PubMedCrossRef

Grulich AE, Wan X, Law MG, Coates M, Kaldor JM (1999) Risk of cancer in people with AIDS. AIDS 13:839–843PubMedCrossRef

Hallek M, Bergsagel PL, Anderson KC (1998) Multiple Myeloma: increasing evidence for a multistep transformation process. Blood 91(1):3–21PubMed

Jaffé ESHN, Stein H, Vardiman JW (eds) (2001) Pathology and genetics of tumours of hematopoietic and lymphoid tissues. IARC Press, Lyon

Kim JH, Bang Y-J, Park BJ, Yoo T, Kim CW, Kim T-Y, Heo DS, Lee H-S, Kim NK (2002) Hepatitis B virus infection and B-cell non-Hodgkin’s lymphoma in a hepatitis B endemic area: a case-control study. Jpn J Cancer Res 93:471–477PubMedCrossRef

Kinlen L (2004) Infections and immune factors in cancer: the role of epidemiology. Oncogene 23:6341–6348PubMedCrossRef

Klein U, Tu Y, Stolovitzky GA, Mattiolo A, Cattoretti G, Husson H, Freedmann A, Inghirami G, Cro L, Baldini L, Neri A, Califano A, Dalla-Favera R (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 194(11):1625–1638PubMedCrossRef

Kuniyoshi M, Nakamuta M, Sakai H, Enjoji M, Kinukawa N, Kotoh K, Fukutomi M, Yokota M, Nishi H, Iwamoto H, Uike N, Nishimura J, Inaba S, Maeda Y, Nawata H, Muta K (2001) Prevalence of hepatitis B or C virus infections in patients with non-Hodgkin’s lymphoma. J Gastroenterol Hepatol 16:215–219PubMedCrossRef

Marcucci F, Mele A, Spada E, Candidi A, Bianco E, Pulsioni A, Chionne P, Madonna E, Cotichini R, Barbui A, de Renzo A, Dore F, Iannitto E, Liso V, Martino B, Montanaro M, Pagano L, Musto P, Rapicetta M (2006) High prevalence of hepatitis B virus infection in B-cell non-Hodgkin’s lymphoma. Haematologica 91:554–557PubMed

Michalak TI (2000) Occult persistence and lymphotropism of hepadnaviral infection: insights from the woodchuck viral hepatitis model. Immunol Rev 174:98–111PubMedCrossRef

Murakami Y, Minami M, Daimon Y, Okanoue T (2004) Hepatitis B virus DNA in liver, serum, and peripheral blood mononuclear cells after the clearance of serum hepatitis B virus surface antigen. J Med Virol 72:203–214PubMedCrossRef

Murray F, Darzentas N, Hadzidimitriou A, Tobin G, Boudjogra M, Scielzo C, Laoutaris N, Karlsson K, Baran-Marzsak F, Tsaftaris A, Moreno C, Anagnostopoulos A, Caligaris-Cappio F, Vaur D, Ouzounis C, Belessi C, Ghia P, Rosenquist R, Stamatopoulos K (2008) Stereotyped patterns of somatic hypermutation in subsets of patients with chronic lymphocytic leukemia: implications for the role of antigen selection in leukemogenesis. Blood 111(3):1524–1533PubMedCrossRef

Nieters A, Kallinowski B, Brennan P, Ott M, Maynadié M, Benavente Y, Foretova L, Cocco PL, Staines A, Vornanen M, Whitby D, Boffetta P, Becker N, de Sanjosé S (2006) Hepatitis C and risk of lymphoma: results of the European Multicenter Case-Control Study EPILYMPH. Gastroenterology 131:1879–1886PubMedCrossRef

Park SC, Jeong S-H, Kim J, Han CJ, Kim YC, Choi KS, Cho JH, Lee M, Jung HH, Ki SS, Chang YH, Lee SS, Park YH, Lee KH (2008) High prevalence of Hepatitis virus infection in patients with B-cell non-Hodgkin’s lymphoma in Korea. J Med Virol 80:960–966PubMedCrossRef

Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37:S4–S66PubMedCrossRef

Quinlan SC, Morton LM, Pfeiffer RM, Anderson LA, Landgren O, Warren JL, Engels EA (2010) Increased risk for lymphoid and myeloid neoplasms in elderly solid-organ transplant recipients. Cancer Epidemiol Biomarkers Prev 19:1229–1237PubMedCrossRef

Raimondo G, Allain J-P, Brunetto MR, Buendia M-A, Chen D-S, Colombo M, Craxí A, Donato F, Ferrari C, Gaeta GB, Gerlich WH, Levrero M, Locarnini S, Michalak T, Mondelli MU, Pawlotsky J-M, Pollicino T, Prati D, Pueti M, Samuel D, Shouval D, Smedile A, Squadrito G, Trépo C, Villa E, Will H, Zanetti AR, Zoulim F (2008) Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol 49:652–657PubMedCrossRef

Rehermann B, Ferrari C, Pasquinelli C, Chisari FV (1996) The hepatitis B virus persists for decades after patients′ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med 10:1104–1108

Shepard CW, Simard EP, Finelli L, Fiore AE, Bell BP (2006) Hepatitis B virus infection: epidemiology and vaccination. Epidem Rev 28:112–125CrossRef

Suarez F, Lortholary O, Hermine O, Lecuit M (2006) Infection-associated lymphomas derived from marginal zone B cells: a model of antigen-driven lymphoproliferation. Blood 107:3034–3044PubMedCrossRef

Wang F, Xu R, Han B, Shi Y, Luo H, Jiang W, Lin T, Huang H, Xia Z, Guan Z (2007) High incidence of hepatitis B virus infection in B-cell subtype non-Hodgkin lymphoma compared with other cancers. Cancer 109:1360–1364PubMedCrossRef

Yood UM, Quesenberry CB, Guo D, Caldwell G, Wells K, Shan J, Sanders L, Skovron ML, Iloeje U, Manos MM (2007) Incidence of non-Hodgkin’s lymphoma among individuals with chronic hepatitis B virus infection. Hepatology 46:107–112CrossRef

Zenz T, Mertens D, Küppers R, Döhner H, Stilgenbauer S (2010) From pathogenesis to treatment of chronic lymphocytic leukaemia. Nat Rev Cancer 10:37–50PubMed

Title: Hepatitis B virus infection and risk of lymphoma: results of a serological analysis within the European case–control study Epilymph
Authors: Nikolaus Becker
Paul Schnitzler
Paolo Boffetta
Paul Brennan
Lenka Foretova
Marc Maynadié
Alexandra Nieters
Anthony Staines
Yolanda Benavente
Pierluigi Cocco
Silvia de Sanjose
Publication date: 01-12-2012
Publisher: Springer-Verlag
Published in: Journal of Cancer Research and Clinical Oncology / Issue 12/2012
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-012-1279-y

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 12/2012

Combined Erlotinib and Cetuximab overcome the acquired resistance to epidermal growth factor receptors tyrosine kinase inhibitor in non-small-cell lung cancer

Identification of heat shock protein 27 as a radioresistance-related protein in nasopharyngeal carcinoma cells

p12CDK2-AP1 inhibits breast cancer cell proliferation and in vivo tumor growth

The preventative effects of sunitinib malate observed in the course from non-castration to castration LNCaP xenograft prostate tumors

Early neutrophil-to-lymphocyte ratio reduction as a surrogate marker of prognosis in never smokers with advanced lung adenocarcinoma receiving gefitinib or standard chemotherapy as first-line therapy

Molecular markers of glioma: an update on recent progress and perspectives

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials